BASF bids €664m for omega-3 company


BASF is to spend €664 million (£530 million) to buy Norwegian firm Pronova BioPharma, which specialises in omega-3 fatty acids. It has the backing of the Pronova board and shareholders representing 60% of the company, including private equity fund Herkules, which owns a 50% stake.

Pronova makes active pharmaceutical ingredients based on omega-3 fatty acids that are used to treat cardiovascular conditions. It also makes dietary supplements.

BASF says that omega-3 fatty acids represent a growing market. The company gained a significant stake in the market through its €3.1 billion purchase of german speciality chemical company Cognis in 2010. It strengthened its position in May this year when it bought UK firm Equateq.

Pronova employs 300 people and makes annual sales of about NOK1.7 billion (£180 million).


Related Content

BASF ups Pronova bid

16 January 2013 Business

news image

Pronova BioPharma specialises in omega-3 fatty acids

BASF to cut 260 jobs in nutrition and health

1 May 2014 Business

news image

Firm to sell Norwegian site and shift focus towards Asia

Most Read

First pictures of hydrogen bonds unveiled

26 September 2013 Research

news image

Observation of intermolecular interactions in quinolines could help to settle the nature of this kind of bonding

Copper catalysis overcomes double bond trouble

3 July 2015 Research

news image

Stubbornly stable unactivated internal alkenes become chiral tertiary amine precursors

Most Commented

Collaboration, not competition

29 June 2015 Research

news image

Organic chemist E J Corey talks to Phillip Broadwith about awards, ambition and academic freedom

Z machine puts the squeeze on metallic deuterium

25 June 2015 Research

news image

Pressures similar to those at centre of the Earth forge metallic deuterium in step toward 80-year-old dream of creating metal...